December 29, 2025 · Form 4 insider transaction
GENMAB A/S bought 1,052,806 shares of MRUS at $97.00 per share, a transaction worth $102.12M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 1 day after the transaction.
On December 12, 2025, Purchaser commenced a subsequent offering period during which Purchaser acquired an additional 1,365,432 Common Shares (as previously reported), as well as an additional 2,978 Common Shares on December 26, 2025 and 1,052,806 Common Shares on December 29, 2025. Parent, as the parent entity of Purchaser, beneficially owned the Common Shares held directly by Purchaser.; The common shares, nominal value EUR 0.09 per share (each, a "Common Share," and collectively, the "Common Shares"), of the Issuer reported herein were held of record by Genmab Holding II B.V. ("Purchaser"), a wholly owned subsidiary of Genmab A/S ("Parent"). Parent, as the parent entity of Purchaser, beneficially owns the Common Shares reported herein.